Stryker Corporation (SYK) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, SYK scores 67 out of 100 (letter grade C+; verdict: Roarable Hold — Upper Neutral / Watch for Breakout). The five pillars are: Fundamental Cash Engine 16/20 (ROIC 11.6%; FCF yield 3.58%), Whale 13F Flow 13/20 (institutional accumulation and options positioning), Insider Conviction 14/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 8/20 (Beta 1.13; sector sensitivity), and Forensic Balance Sheet 16/20 (Altman Z 4.46; Piotroski F 9/9; Debt/Equity 0.66).

Investor implications: the strongest pillars are cash generation and balance-sheet forensics, which support the view that the business is financially sound. The weakest pillar is macro regime fit, where a beta of 1.13 indicates the stock has historically moved somewhat more than the market, creating exposure to broader risk-off periods. The valuation tradeoff is visible in the market data: a P/E (TTM) of 36.8 and an EV/EBITDA of 23.6 are premium multiples, and the FCF yield of 3.58% is modest, so upside depends on continued earnings growth rather than a cheap entry point. The verdict's "Watch for Breakout" language signals the rating sees the stock as neutral today, with a potential move higher contingent on catalysts rather than current pricing.

Stryker Corporation is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry, per the profile section. Not available in source data for product lines, customer segments, or revenue model detail. The company's scale is reflected in its market capitalization of $119.6B and reported FY 2025 revenue of $25116.0M per the SEC financials.

Per the market data, gross margin is 64%, operating margin 19.5%, and net margin 12.9%, with ROIC of 11.6%. Per the Roarable RQD rating, the forensic balance sheet pillar reflects an Altman Z-Score of 4.46, a Piotroski F-Score of 9/9, and Debt/Equity of 0.66. Reported revenue and operating income rose across the three periods shown, while debt also rose from $12188.0M to $14859.0M between FY 2024 and FY 2025. Cash was not reported for FY 2023.

The news wire contains six items, all tagged to SYK:

• GREEN / CATALYST: "Is Stryker Corp. (SYK) Positioned for Above-Market Growth?" (Yahoo Finance) and "Stryker: This Dividend Aristocrat Is Finally Cheap Again" (Seeking Alpha). Both are flagged as potential positive catalysts; the second headline's framing suggests a valuation argument, which should be weighed against the premium multiples in the market data.
• YELLOW / MARKET WIRE: "Stryker Corp Stock (SYK) Moved Up by 3.32% on Oct 5" (TradingKey), "Stryker Stock Price Forecast. Should You Buy SYK?" (StockInvest.us), and "Stryker (SYK) vs Boston Scientific (BSX)" (Yahoo Finance). These are neutral-status market commentary.
• RED / RISK WATCH: "Stryker Shares Fall 11.8% After Hours After Q3 Earnings Miss" (Benzinga). This is the single risk-flagged item and the most important near-term item to reconcile against the bullish headlines.

The Butterfly Supply-Chain Graph reports supply_chain as NONE, with no butterfly links and no proprietary signals.

• What drove the reported Q3 earnings miss and the 11.8% after-hours decline, and how does it reconcile with the FY 2025 growth shown in the SEC financials?
• Why is FY 2023 cash and EPS unavailable, and can the EPS gap across all three periods be filled from the filings?
• What is the composition of the rise in debt from $12188.0M to $14859.0M, and how does it affect the 0.66 Debt/Equity reading?
• Which institutional holders and insider transactions underlie the 13/20 whale and 14/20 insider pillar scores?
• What product, customer, and supplier relationships connect SYK to the broader Medical/Dental Instruments industry?